VANCOUVER, November 5 /PRNewswire/ -- Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that it has signed its first Contribution Agreement with the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). This research funding will be used to study genomic correlations in severe sepsis patients. Specifically, the contribution will go towards the continued development of Sirius' pharmacogenomic diagnostic intended to assess responsiveness to recombinant human activated Protein C (developed and marketed by Eli Lilly and Company under the trademark Xigris (R)) in patients with severe sepsis at high risk of death.

Dr. Brad Popovich, President and CEO of Sirius Genomics, comments, This financial support demonstrates the willingness of the Canadian government to sustain innovation in critical areas of growth such as genomics and personalized medicine. The program provides an important service for small, rapidly growing Canadian companies such as ours.

NRC-IRAP provides a range of both technical and business-oriented advisory services along with potential financial support to qualified innovative Canadian small- and medium-sized enterprises. Financial assistance for this project is a direct result of the Government of Canada's Economic Action Plan. More information about NRC-IRAP is available at

About Sirius Genomics:

Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

For further information: Chris Wagner, Vice President Business Development, Sirius Genomics, +1(604)484-7195,

SOURCE: Sirius Genomics Inc.

CONTACT: For further information: Chris Wagner, Vice President BusinessDevelopment, Sirius Genomics, +1(604)484-7195,